Defunct Company
Total Trials
6
As Lead Sponsor
5
As Collaborator
1
Total Enrollment
299
NCT01775358
Phase 1 Safety Study of ALRN-5281 in Healthy Subjects
Phase: Phase 1
Role: Lead Sponsor
Start: Jan 31, 2013
Completion: May 31, 2013
NCT02264613
ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas
Phase: Phase 1/2
Start: Oct 31, 2014
Completion: Apr 30, 2020
NCT02909972
Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
Start: Sep 30, 2016
Completion: Aug 31, 2019
NCT03654716
Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer
Role: Collaborator
Start: Nov 1, 2018
Completion: Jul 17, 2023
NCT04022876
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
Start: Sep 3, 2019
Completion: Aug 30, 2022
NCT05622058
A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer
Start: Jan 9, 2023
Completion: Feb 22, 2023